Trials / Terminated
TerminatedNCT02614898
Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment
Evidence - Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 67 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This was a prospective, open-label study with no participant randomization. Treatment for aHUS was observational and at the discretion of the treating physician. The purpose of this study was to assess disease manifestations of complement-mediated thrombotic microangiopathy (TMA) and evaluate potential clinical predictors of disease manifestations and progression in participants with aHUS with or without eculizumab treatment in the clinical setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Eculizumab | This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician. |
Timeline
- Start date
- 2015-11-04
- Primary completion
- 2017-10-05
- Completion
- 2017-10-05
- First posted
- 2015-11-25
- Last updated
- 2020-01-02
- Results posted
- 2020-01-02
Locations
24 sites across 4 countries: United States, Australia, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT02614898. Inclusion in this directory is not an endorsement.